GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

AI Briefing

• – GENFIT's NTZ receives FDA Orphan Drug Designation for ACLF treatment.
• – NTZ is a small-molecule drug candidate for the treatment of Acute-on-Chronic Liver Failure (ACLF).
• – GENFIT is dedicated to improving the lives of patients with rare and life-threatening liver diseases.